Skye Bioscience, Inc.

The momentum for this stock is not very good. Skye Bioscience, Inc. is not a good growth stock. Skye Bioscience, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Skye Bioscience, Inc..

News

Skye Bioscience (NASDAQ:SKYE) Trading Down 9.2%

Ticker Report Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) fell 9.2% on Wednesday . The company traded as low as $6.33 and last traded at $6.35. 593,578 shares changed hands during mid-day trading, an...\n more…

Skye Bioscience initiated with bullish view at JMP Securities, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Skye Bioscience (NASDAQ:SKYE) Receives Overweight Rating from Cantor Fitzgerald

Ticker Report Cantor Fitzgerald reiterated their overweight rating on shares of Skye Bioscience (NASDAQ:SKYE - Free Report) in a report released on Friday, Benzinga reports. The firm currently has a $14.00 price...\n more…

Skye Bioscience (NASDAQ:SKYE) Rating Reiterated by Cantor Fitzgerald

Ticker Report Cantor Fitzgerald restated their overweight rating on shares of Skye Bioscience (NASDAQ:SKYE - Free Report) in a report published on Friday, Benzinga reports. They currently have a $14.00 target...\n more…

Skye Bioscience (SKYE) Gets a Buy from Piper Sandler

TipRanks Financial Blog In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Skye Bioscience (SKYE - Research Report), with a price ta...\n more…

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

Globe Newswire SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ( Skye ), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...\n more…